Nuvalent, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 44.48 million compared to USD 25.19 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 0.44 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
69.82 USD | +0.13% | -2.59% | -5.12% |
May. 17 | Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing | MT |
May. 16 | Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.12% | 4.51B | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.66% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+25.72% | 12.26B | |
+27.17% | 12.05B |
- Stock Market
- Equities
- NUVL Stock
- News Nuvalent, Inc.
- Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024